The company began operation in February 2010 and since its formation has secured in excess of AU$10 million of investment.
A Series A investment was secured in January 2011 and a AU$9.2 million Series B investment was made in January 2013. The Series B investment was made by a syndicate of investors including Medical Research and Commercialisation Fund (MRCF) and Brandon Biosciences Fund 1 (BBF1) – both managed by Brandon Capital Partners, and Yuuwa – managed by Yuuwa Capital.
PolyActiva’s platform technology is used to deliver drugs to specific sites in the body with control over the rate of drug delivery for up to 12-months. The technology involves formation of a polymeric prodrug of the target drug, which in turn is the sole component used to produce the administered product. The product administered to the site can take various forms, including rod-shaped implants, injectable gels, and topical film. The technology enables product with high dose loads, which means sufficient drug can be carried in products of a very small size and still delivery therapeutic daily doses to the therapeutic site over extended periods. All of our products are designed to biodegrade after the treatment period, and leave no residue. As a consequence, PolyActiva’s delivery technology is very well suited to delivery at site of the body that have limited volumes (e.g. the eye). With the PolyActiva technology, exceptional zero-order release profiles are achieved over treatment periods ranging from 1 to 12 months. The process by which we manufacture our products is robust, scalable, and can be adapted to existing device component production processes. PolyActiva has built a number of products with drug candidates from different drug classes and with different linkage points, demonstrating the plasticity of the technology.
We have also developed a number of functional co-monomers and polymer segments, which modularises the production of the final polymeric prodrug. Analogous to a set of Lego®, we now have the various building blocks from which we can select to build the preferred polymer prodrug. Animal studies are now complete for our first two ocular products and work towards clinical development has been initiated.
The company is headquartered at Queen Street, Melbourne, with research facilities at Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Melbourne.
The company has secured a world-class team of more than 10 staff that provide the core chemistry and development capabilities. We also have established relationships with key research service providers including MIPS, University of Melbourne, CERA, MSU, Bolder BioPATH, Institute of Bone and Joint Research, and Miguel Hernandez University who provide capabilities in pharmaceutical chemistry, polymer chemistry, ophthalmology and animal models.